 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Enrollment closed: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (clinicaltrials.gov) - Jul 29, 2024
P2, N=72, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Recruiting --> Active, not recruiting
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Trial completion date, Trial primary completion date: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (clinicaltrials.gov) - Apr 7, 2024
P2, N=72, Recruiting, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Recruiting --> Active, not recruiting Trial completion date: Jun 2024 --> Feb 2025 | Trial primary completion date: Mar 2024 --> Nov 2024
- | unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Phase classification: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (clinicaltrials.gov) - Feb 15, 2024
P2, N=72, Recruiting, Sponsor: Mitsubishi Tanabe Pharma America Inc.
Trial completion date: Jun 2024 --> Feb 2025 | Trial primary completion date: Mar 2024 --> Nov 2024 Phase classification: P2a --> P2
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Trial completion: A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) (clinicaltrials.gov) - Jan 28, 2024
P1, N=15, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Phase classification: P2a --> P2 Active, not recruiting --> Completed
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Enrollment closed: A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) (clinicaltrials.gov) - Apr 20, 2023
P1, N=15, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Trial completion date, Trial primary completion date: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (clinicaltrials.gov) - Mar 2, 2023
P2a, N=72, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Recruiting --> Active, not recruiting Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Mar 2024
- || unasnemab (MT-3921) / Mitsubishi Tanabe
Trial completion: A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males (clinicaltrials.gov) - Jan 18, 2023
P1, N=10, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Mar 2024 Recruiting --> Completed
- || unasnemab (MT-3921) / Mitsubishi Tanabe
Enrollment open: A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males (clinicaltrials.gov) - Aug 24, 2022
P1, N=10, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- || unasnemab (MT-3921) / Mitsubishi Tanabe
New P1 trial: A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males (clinicaltrials.gov) - May 30, 2022
P1, N=10, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Enrollment open: A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) (clinicaltrials.gov) - May 16, 2022
P1, N=15, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
New P1 trial: A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) (clinicaltrials.gov) - Feb 15, 2022
P1, N=15, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||| unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
Enrollment open: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (clinicaltrials.gov) - Jul 28, 2021
P2a, N=72, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || unasnemab (MT-3921) / Mitsubishi Tanabe
Trial completion: Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury (clinicaltrials.gov) - Feb 16, 2021
P1, N=3, Completed, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| unasnemab (MT-3921) / Mitsubishi Tanabe, Osaka University
New P2a trial: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (clinicaltrials.gov) - Dec 23, 2020
P2a, N=72, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
- | unasnemab (MT-3921) / Mitsubishi Tanabe
Enrollment closed, Trial primary completion date: Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury (clinicaltrials.gov) - Dec 11, 2020
P1, N=3, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2021
- || unasnemab (MT-3921) / Mitsubishi Tanabe
Enrollment open, Trial initiation date: Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury (clinicaltrials.gov) - Dec 1, 2019
P1, N=6, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2021 Not yet recruiting --> Recruiting | Initiation date: Oct 2019 --> Jan 2020
- | unasnemab (MT-3921) / Mitsubishi Tanabe
New P1 trial: Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury (clinicaltrials.gov) - Sep 19, 2019
P1, N=6, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.